Creation of drug efficacy prediction system based on ultrasensitive protein profiling using human iPS cells

2022 Fiscal Year Final Research Report

• Project/Area Number: 19K07119
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Review Section: Basic Section 47040:Pharmacology-related
• Research Institution: University of Toyama
• Principal Investigator: Kume Toshiaki 富山大学, 学術研究部薬学・和漢系, 教授 (10303843)
• Project Period (FY): 2019-04-01 – 2023-03-31
• Keywords: タンパク質プロファイリング / アルツハイマー病

Outline of Final Research Achievements

There is currently no established fundamental treatment for neurodegenerative diseases like Alzheimer's disease (AD), and there is increasing hope for preemptive medicine through early intervention. However, no biomarkers have been discovered to facilitate its implementation. In this study, instead of solely focusing on individual protein variations, we employed protein profiling technology to comprehensively collect patterns of protein variation. Multiple protein variation patterns were then identified as potential disease biomarkers. Initially, our plan was to conduct basic research on their application. However, due to various circumstances, we shifted our focus to investigating the mechanism of toxicity manifestation in AD model mice and the three-dimensional structure of Aβ, which plays a crucial role in its onset. By doing so, we aimed to elucidate the contributing factors involved.

Free Research Field

神経薬理学

Academic Significance and Societal Importance of the Research Achievements

本研究により、脳疾患と関連するタンパク質のプロファイルに関する新たな知見が得られることが期待されます。これにより、脳の病理学や疾患の発症機構についてより深い理解が可能になります。また、新しいタンパク質プロファイリング技術の開発や改良は、医学研究における重要な手法の進歩を促進することが期待されます。社会的意義については、脳疾患における早期診断と個別化された治療法の開発は、患者の生活の質を向上させる重要な要素であり、バイオマーカーの創出は、脳疾患の早期検出や効果的な治療法の開発に寄与することが期待されます。